Research Hub

대학 자원

대학 인프라와 자원을 공유해 공동 연구와 기술 활용을 지원합니다.

Loading...

논문 리스트

2019
Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
대한혈액학회
논문정보
Publisher
Blood Research
Issue Date
2019-12-20
Keywords
-
Citation
-
Source
-
Journal Title
-
Volume
54
Number
4
Start Page
244
End Page
252
DOI
ISSN
2287979X
Abstract
BackgroundSystemic inflammatory response can be associated with the prognosis of diffuse large B cell lymphoma (DLBCL). We investigated the systemic factors significantly related to clinical outcome in relapsed/refractory DLBCL.MethodsIn 242 patients with DLBCL, several factors, including inflammatory markers were analyzed. We assessed for the correlation between the survivals [progression-free surviv-al (PFS) and overall survival (OS)] and prognostic factors. ResultsIn these patients, a high derived neutrophil/lymphocyte ratio (dNLR) (PFS, HR=2.452, P=0.002; OS, HR=2.542, P=0.005), high Glasgow Prognostic Score (GPS) (PFS, HR=2.435, P=0.002; OS, HR=2.621, P=0.002), and high NCCN-IPI (PFS, HR=2.836, P=0.003; OS, HR=2.928, P=0.003) were significantly associated with survival in multi-variate analysis. Moreover, we proposed a risk stratification model based on dNLR, GPS, and NCCN-IPI, thereby distributing patients into 4 risk groups. There were significant differences in survival among the 4 risk groups (PFS, P<0.001; OS, P<0.001). ConclusionIn conclusion, dNLR, GPS, and NCCN-IPI appear to be excellent prognostic parameters for survival in relapsed/refractory DLBCL.

저자 정보

이름 소속
등록된 데이터가 없습니다.